STOCK TITAN

Nascent Biotech Inc - NBIO STOCK NEWS

Welcome to our dedicated news page for Nascent Biotech (Ticker: NBIO), a resource for investors and traders seeking the latest updates and insights on Nascent Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nascent Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nascent Biotech's position in the market.

Rhea-AI Summary
Nascent Biotech, Inc. (NBIO) announced a research collaboration agreement with Manhattan BioSolutions, Inc. to explore antibody-drug conjugates using Nascent's lead clinical candidate pritumumab (PTB) as the tumor-targeting antibody element. PTB is a natural human antibody that targets extracellular vimentin, a protein linked to cancer growth. It has demonstrated safety and preliminary efficacy in Phase I study in glioblastoma patients. Nascent has FDA clearance to begin Phase II clinical trials for brain cancer. The collaboration aims to prioritize promising ADC candidates for the treatment of vimentin-positive and potential secondary targets in advanced or metastatic tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.41%
Tags
none
-
Rhea-AI Summary
Nascent Biotech, Inc. (NBIO) analysts suggest value at $0.60 to $2.84 per share. The company is a clinical-stage biotechnology company developing monoclonal antibodies focused on treating various cancers. Nascent was featured in an independent research report by Marble Arch Research, highlighting the investment potential of their common stock. The report underscores the company's conviction that their stock is undervalued. CEO Sean Carrick remarks on the potential breakthrough therapy of Pritumumab (PTB) in the $1.8 billion underserved brain cancer market, demonstrating safety, efficacy, and the ability to breach the blood-brain barrier to attack brain cancer cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.35%
Tags
none
-
Rhea-AI Summary
Nascent Biotech, Inc. (OTCQB:NBIO) has announced the completion of payment of all outstanding variable convertible debt obligations, demonstrating their commitment to prioritize shareholder interests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
none
Rhea-AI Summary
Nascent Biotech, Inc. (NBIO) has been issued a 'Method-of-Use' patent from the Japanese Patent Office for its primary asset, Pritumumab (PTB), related to PTB's capacity to cross through the Blood-Brain Barrier. The patent approval recognizes PTB's ability to act as a monotherapy and as a conjugate, bringing other therapies across the BBB. Nascent's senior management sees this as a significant event elevating the Company's value proposition and strengthening its intellectual property position internationally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
-
Rhea-AI Summary
Nascent Biotech cleared by FDA for Phase II clinical trials for brain cancer with its therapeutic antibody Pritumumab (PTB).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.6%
Tags
clinical trial
-
Rhea-AI Summary
Nascent Biotech presented their Phase I Clinical Data at the American Society of Clinical Oncology (ASCO) meeting. The data showed the drug to be very safe at 5 ascending dose cohorts and demonstrated bioactivity in several patients. The therapeutic antibody Pritumumab (PTB) targets cell surface Vimentin and recruits the immune system to eliminate cancer cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.56%
Tags
clinical trial
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.8%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.51%
Tags
clinical trial
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.9%
Tags
clinical trial
Nascent Biotech Inc

OTC:NBIO

NBIO Rankings

NBIO Stock Data

19.08M
93.92M
41.13%
0.63%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
North Palm Beach

About NBIO

nascent biotech, inc. (otcmkts:nbio) is a public company, formed in march 2014, to continue development of pritumumab, a human monoclonal antibody created by a number of leading scientists who have developed various monoclonal antibodies and cytokine treatments for oncology indications. pritumumab recognizes a unique and proprietary antigen expressed on the surface of cancer cells and is being developed to treat brain and pancreatic cancers, both unmet clinical needs. nbio’s clinical premise is that the most effective way to treat disease is to modulate (boost or suppress) the human body’s natural ability to generate an immune response. often referred to as “immunotherapy”, the scientific approach is based upon two discrete types of regulatory molecules, monoclonal antibodies and cytokines that can be combined to maximize therapeutic effectiveness in a variety of diseases. monoclonal antibodies (mabs) are naturally occurring proteins that bind with exquisite specificity to molecular st